Characteristic	Treatment Cohorts			
	Aspirin (N=60)	Warfarin (N=28)	NOAC (N=194)	Total (N=282)
Age (Years)				
Age (Years)				
N	60	28	194	282
Mean	52.3	58.2	50.1	51.3
Median	57.1	58.8	50.0	52.3
Min, Max	18, 90	38, 83	18, 92	18, 92
Standard Deviation	21.83	11.99	19.19	19.31
Gender (%)				
Male	33 (55.0%)	15 (53.6%)	101 (52.1%)	0 (0.0%)
Female	27 (45.0%)	13 (46.4%)	93 (47.9%)	0 (0.0%)
Race (%)				
White	39 (65.0%)	21 (75.0%)	133 (68.6%)	0 (0.0%)
Asian	3 (5.0%)	1 (3.6%)	5 (2.6%)	0 (0.0%)
AmericanIndianOrAlaskaNative	4 (6.7%)	0 (0.0%)	7 (3.6%)	0 (0.0%)
NativeHawaiianOrOtherPacific Islander	6 (10.0%)	1 (3.6%)	9 (4.6%)	0 (0.0%)
OtherRace	4 (6.7%)	1 (3.6%)	12 (6.2%)	0 (0.0%)
Unknown	4 (6.7%)	2 (7.1%)	16 (8.2%)	0 (0.0%)
CHA2DS2-VASc Score				
Mean (SD)	6.17 (1.14)	6.68 (1.25)	6.84 (0.90)	. (.)
0-2	0 (0.0%)	1 (3.6%)	1 (0.5%)	0 (0.0%)
3	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	2 (3.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
>=5	57 (95.0%)	27 (96.4%)	193 (99.5%)	0 (0.0%)
HAS-BLED Score				
Mean (SD)	4.05 (0.67)	3.50 (0.88)	3.81 (0.94)	. (.)
0-2	3 (5.0%)	1 (3.6%)	1 (0.5%)	0 (0.0%)
>=3	57 (95.0%)	27 (96.4%)	193 (99.5%)	0 (0.0%)
Age Categorization (%)				
<65	38 (63.3%)	19 (67.9%)	141 (72.7%)	0 (0.0%)
65-75	12 (20.0%)	6 (21.4%)	31 (16.0%)	0 (0.0%)
>75	10 (16.7%)	3 (10.7%)	22 (11.3%)	0 (0.0%)

	Treatment Cohorts			
Characteristic	**Aspirin (N=60)**	**Warfarin (N=28)**	**NOAC (N=194)**	**Total (N=282)**
Year of Diagnosis of AF				
2020	15 (25.0%)	7 (25.0%)	50 (25.8%)	0 (0.0%)
2019	42 (70.0%)	20 (71.4%)	143 (73.7%)	0 (0.0%)
2018	3 (5.0%)	1 (3.6%)	1 (0.5%)	0 (0.0%)